Investor. Opinions my own. Not financial nor any kind of advice.

San Francisco, CA
Joined January 2015
Matheus Lonning retweeted
this is the 17 day rate of change of the MS Tech Mo Factor. -35%, worst in 27 year history.
33
35
20
367
144,930
Matheus Lonning retweeted
Going to pump so hard when this gets postponed
JUST IN: 🇺🇸🇮🇷 President Trump says he will "bomb the shit" out of Iran if they do not sign a deal by tomorrow.
1
1
13
2,498
Matheus Lonning retweeted
I think $TRT files their 10q tomorrow. I could be wrong. I think they grow semiconductor revs ~140% YoY. Cannot wait.
4
2
1
22
7,919
Matheus Lonning retweeted
Can't wait for $APP to beat, raise, produce 85% net income margins, and proceed to sell-off.
5
4
56
5,745
Matheus Lonning retweeted
Undervalued and under followed small caps set to outperform: $IEHC: makes hyperboloid connectors and custom interconnect products used in harsh, high-reliability applications, especially defense, aerospace, and industrial systems. The undervaluation case is that the market still seems to treat it like a tiny illiquid niche manufacturer even though FY2025 revenue rose 33.7%, it swung back to profitability, and backlog reached record levels tied to missile, radar, and air-defense programs. Accounting issues have been resolved and the company operates in a duopoly for critical aerospace parts. $TRT: provides semiconductor back-end services like testing and burn-in plus industrial electronics manufacturing, with most of its footprint in Asia. The stock looks undervalued because it is a microcap with limited attention, but management is explicitly calling out continued fiscal 2026 demand from advanced and AI-related device programs while also expecting more contribution from its Industrial Electronics segment. Downside is supported by net cash position + aerospace business. Upside comes from the semiconductor sector growing 100%+ YoY. $ACMR: makes wafer-cleaning and other semiconductor equipment used by chip manufacturers, with exposure across foundry/logic, memory, and advanced packaging. The undervaluation argument is that the stock got hit by near-term earnings noise and geopolitical concerns, while the business still guided for 2026 revenue growth of roughly 21% to 30%, ended 2025 with $845 million of net cash, and is showing progress with global customers outside China. $WSTL: sells network infrastructure products, especially in-building wireless/public safety coverage solutions plus broadband and site management equipment. The undervaluation case is mostly asset-based, it has been gaining traction in public safety and rural broadband, downside is limited due to strong net cash position and also has NOLs that could matter if profitability improves, this one is more speculative than the others because execution still needs to show up consistently in results. Though the company may experience strong results if execution is sustained. $BUKS: designs, modifies, services, and installs specialized aerospace systems and aircraft components through its aerospace business, while also owning a gaming-management/services segment. The undervaluation case is that the market appears to still treat it like an obscure OTC conglomerate even as aerospace is becoming the real value driver, with the company highlighting ongoing investment in new products, continued share repurchases, and recent FAA approval for new aircraft modification capabilities that can support higher-margin growth. $TMDX: OCS + NOP = MOAT.
3
3
42
5,086
Matheus Lonning retweeted
There are a lot of high flying semiconductor companies out there trading at insane multiple who won’t produce any FCF for the next several quarters. Hidden in micro-cap land, there is $TRT who’s already produces FCF, is growing semiconductor revenues 100%+ YoY and continues to ramp up burn-in solutions, having received a $2.5M order today. (Market cap ~$45M). They are going to continue accelerating growth as the burn-in test systems have been well received by customers. The company is deeply undervalued. There are many risks as I have covered on my article, but the upside is 10x. When they report earnings again, sometime in May, the re rating will likely be aggressive. Why buy a stock when up 200%+ in a month, when you can buy it before the run-up? I urge you to read the company’s 10k and see for yourself. Incredible opportunity, in my opinion.
6
4
1
36
7,024
Matheus Lonning retweeted
Yep. It’s going back to $70.
Retail Traders plowed $211 million into Oil ETFs on Thursday, the largest inflow in history 🚨🚨🚨
70
53
5
1,297
150,574
Matheus Lonning retweeted
LIVE: Hedge fund manager @mathlonning Tune in for a great conversation with one of the young minds dominating the fund space. You don't want to miss this 👇 xitter.cf/i/broadcasts/1jGXgewYZ…
16
7
4
96
788,321
Matheus Lonning retweeted
$TMDX March Transplant Update Huge month for DCD transplant volume with an all time high in both Liver and Heart. This is similar to last year where transplant volumes spiked in March and continued that momentum into Q2. - Total Transplant Volume: 1,747 (9% MoM, +2% YoY) - DCD Volume: 675 (22% MoM, +23% YoY) - DCD Share: 39% of total transplants (vs 32% in March 2025). As a reminder, to meet management's guidance for 2026, I am assuming DCD volume has to increase ~20% YoY, so well on track with YTD DCD volume up 36%. Total Transplant growth is somewhat tepid at 3% growth YTD. Would like to see that inch up closer to 4-5%. Revenue Estimate Based on DCD and Flight data I am assuming $175M for revenue in Q1 with potential upside of $180M. Looking ahead to Q2, historically Transmedics' best quarter, flight data is off to a prodigious pace averaging 35 flights a day. This pace will be needed because I do not think the Q1 results alone warrant a revenue raise from management.
4
4
2
64
15,530
Don't even ask the question. The answer is yes, it's within the collar. Think the S&P is going to rip to new all-time highs? Sorry, there's a short call at 7155 capping your upside. The hedge fund already sold it. You think you found alpha? You found the ceiling of a put spread some quant structured three months ago in a conference room overlooking Park Avenue. You think the market is going to crash? Priced in. There's a long put at 6475 and market makers are going to buy futures all the way down to defend it. You think you're being clever buying puts at 6400? Congratulations, you just paid premium to bet against the gamma hedging flows of the largest bank in the United States. The JPM Collar is an all-powerful, all-encompassing being that knows the very inner workings of every retail trader's Robin Hood account before they even open it. Your portfolio was structured decades ago when JHEQX was valuing its expected quarterly roll based on implied volatility that would lead to your birth, what age you would discover options, how many times you would get wrecked on 0DTEs every week, how many times you would stare at SpotGamma charts pretending to understand them, etc. Anything you can think of has already been collared, even the things you aren't thinking of. You have no original trades. Your "conviction" is just an illusion, a product of the omniscient put spread. Free will is a myth. The collar sees all, knows all, and will be there from the beginning of time until the end of the universe (the collar has already priced in the heat death of the universe and set strikes accordingly, long put at Entropy-5%, short put at Absolute Zero). Every quarter, like clockwork, the high priests at 383 Madison Avenue roll their positions. They sell calls. They buy puts. They sell lower puts. And the entire S&P 500 bends to their will. You think Powell controls the market? Powell wishes he had the gamma exposure of JHEQX. You want to go long? Cool. The ceiling is the short call. You want to go short? Also cool. The floor is the long put. You want to make money? That's the 980 point range they've already defined for you. Stay in your lane. The collar has spoken. So please, before you make a post on wsb asking whether SPX is going to break out, or whether we're going to crash, or what strike to buy, just look up the JPM collar strikes for the quarter. That's your range. That's everyone's range. We're all just trading inside JPMorgan's hedged equity terrarium. Don't fight the collar. The collar is inevitable. The collar is eternal.
market rally? bc of the collar oil down? yep, the collar again claude code leaked? collar's fault my local dive bar running out of springfest IPA? fckin' collar, man the beatles breaking up decades ago? yep, collar libor being replaced years ago? u guessed it, collar
73
94
23
1,259
296,066
Matheus Lonning retweeted
mfs down 50% YTD right now
14
23
627
33,728
Matheus Lonning retweeted
You panicans are wishing you closed those $QQQ puts aren’t you?
3
1
32
5,945
Matheus Lonning retweeted
$tmdx @JonahLupton @KabraxFX @POLR_Investing @mathlonning -Got Jan numbers in from OPTN – everything ties out with what @POLR_Investing shared as well. I also included DBD numbers - which start to become a big deal for not just Liver, but Heart (given ENHANCE). -Purple box shows the highest DCD mix in the last 13 months, and the trendline into that datapoint is clearly up and to the right...... One major company in the industry to thank for that - $tmdx... -Orange liver total boxes (Jan ’25 vs Jan ’26) are basically flat, while liver DCD volumes rise and liver DBD comes down. The story is mix shift, not overall volume growth – needless to say, great for $tmdx., -That pattern in the orange boxes screams impact from one dominant platform: more liver DCD utilization being unlocked while total liver transplants stay roughly constant. $tmdx., -Expect a similar pattern to emerge on the heart side as ENHANCE plays out. The 8% DBD heart market share (end 2024) will be up for 2025 – but whatever that new number is that we see in a few weeks is likely to hockey‑stick higher just like liver did, this time for heart DBD., -For DCD heart, TransMedics already had roughly 67% share in 2024; for DBD heart, they were only around 8%, so the upside from DBD expansion is substantial.
4
7
1
53
16,535
Matheus Lonning retweeted
As markets continue to transition toward algorithm driven trading, periods of correction may resolve more quickly than in prior cycles, creating opportunities for outsized returns for investors willing to tolerate short term PnL volatility. The recent software sell off is a clear example of this dynamic: a severe correction that may resolve in the near term, despite many names experiencing drawdowns of 50% or more over a matter of months. While certain companies may never regain their prior valuation multiples, a subset of fundamentally strong businesses is likely to emerge from the dislocation, offering meaningful opportunities for excess returns. $APP $RBRK $NOW
1
2
1
14
2,948
Matheus Lonning retweeted
$TMDX did 23.8 flights per day in 2025 Q1 so flights in 2026 Q1 are currently tracking +24% YoY but we also know that ground transports have become a bigger % of overall OCS cases over the past 12 months. If we assume ground transports were 30% of OCS cases in 2025 Q1 but they've since increased to 40% of OCS cases in 2026 Q1, then it's possible that total OCS cases are actually up +44.6% YoY Too early to say whether $TMDX can maintain this run rate through the rest of Q1 but if they can, there's no way this YoY growth is currently priced into the stock at 5.5x NTM revs and 22x NTM EBITDA NFA. DYOR. Have a nice weekend. Go PATS!!!!! 🏈
Just updated the $TMDX flight tracker and the numbers look phenomenal. $TMDX did 22.9 flights per day in 2025 Q3 $TMDX did 25.3 flights per day in 2025 Q4. $TMDX did 29.2 flights per day in January 2026. $TMDX has done 31.1 flights per day in February 2026. Flight data definitely trending in the right direction.
3
15
3
186
79,312
Matheus Lonning retweeted
$COHR earnings sure were... exciting? There is a lot to unpack here. That price action definitely could make you question your thesis. But if you dig under the headlines the story is very compelling and I am a buyer. Coming off of a massive $LITE earnings I believe that market had really high expectations for $COHR. But it’s not an apples to apples comparison. There is a massive valuation gap. $LITE deserves the premium because it’s a cleaner, more concentrated AI optics earnings stream, so the growth shows up more directly in the consolidated numbers. $COHR is still a blended story (datacenter + comms plus a real industrial/legacy base), which smooths the headline growth rate even if the datacenter engine growth is solid. COHR can work to close the gap if that datacenter mix keeps rising while 6-inch InP drives a real margin + cash flow inflection and the new legs (OCS + CPO) start showing up as revenue instead of future tense. But that’s why it’s important to know what you own and to be able to dig and see what really matters So lets do just that It’s easy to highlight the good, so let’s start with the “bad” 1- I think most of the initial selloff was due to sticker shock. Even though the earnings were really strong, they weren’t $LITE strong. But they were never going to be. As I mentioned, Lumentum is going to see higher rates of growth. That’s why they trade at a much higher P/S. Lumentum is also more of a pure-play whereas Coherent has a wider base of more legacy revenue streams that aren’t going to grow that fast. So let’s demonstrate this with some number. Coherent did $1.69B this quarter. The key is the mix. Datacenter + Comms is now the engine, but Industrial is still meaningful, so you are not going to get the same pure AI optics quarter-to-quarter profile that the market is heavily rewarding At the same time, the mix shift is accelerating in the right direction. Datacenter + Comms went from about $905M a year ago to about $1.2B this quarter, while Industrial moved from about $530M to about $478M. So the legacy drag is real, but the business is still becoming more AI weighted every quarter. 2 - Cash flow negative? It might feel like a company at this stage should be FCF + (as Lumentum is) but there is a very good reason they aren’t. There was so much reiteration and emphasis on the need/desire to expand their capacity. I see this as a major positive (for anyone with a multi-year investment at least). More on this later, but basically we take a bit of a hit now which opens the door for massive growth and supply later. Capex was $154M this quarter and they basically told you it is going higher sequentially through the rest of the fiscal year. They are choosing to be cash flow ugly now so they can be supply rich later. 3 - Macro uncertainty. We all saw the tape today. Bloody. AMD down big, SAAS down big, high beta down big. Almost everything was under pressure. So the fact that Coherent is at the same price it was at on Monday is pretty solid IMO. If you are a short term trader and bought today, yeah this is rough. I personally bought at $220/$207/$170. But this is my long term hold and my avg. price is way below these levels. Ok, now on to the good 1 - Demand visibility is unusually strong…. They said datacenter book to bill was over 4x. They said orders are moving further out. They said most of calendar 2026 is booked, 2027 is filling quickly, and they are getting customer forecasts into 2028. Then they layered on long-term agreements where customers commit demand and sometimes help fund capacity. This is what you want in an actual capacity buildout. Not only are customers interested but they are planning and committing and a very meaningful way 2 - Margins are improving and there is a plan for even higher as we go along… Non-GAAP gross margin was 39% and they are still talking about a long-term model over 42%. The drivers are BOM and input cost reductions, cycle time and yield improvements, pricing optimization, and then volume. And the portfolio clean-up is crucial as well. They sold the Munich tools business that was about $25M per quarter of low margin revenue, and they explicitly said proceeds go to paying down debt, lowering interest expense, and being immediately accretive. 3 - The InP advantage (and what it actually means) This is the core reason I wanted higher concentration in COHR. Management basically spent the whole call telling us that InP is still the bottleneck, and they don’t expect the supply/demand imbalance to normalize this year or next. That matters because when the industry is short, the winner is not "who has demand”… it’s who can actually ship. (And who can ship profitably.) Now look at what they’re doing about it: 6-inch indium phosphide ramp. They’re producing key transceiver components on 6-inch (EMLs, CW lasers, photodiodes), and they’re framing 6-inch vs 3-inch as 4x+ chips at less than half the cost. That’s a structural manufacturing advantage that should show up in cost, margins, and supply reliability as the 6-inch mix grows. Then stack on top of that the next wave 1.6T is ramping, and they basically said it is margin accretive because ASPs are higher than 800G and early-cycle margins tend to be higher. CPO is being framed as additive TAM, and the big payoff is scale-up, because that network is electrical today. OCS is also getting real. They have 10+ customer engagements, backlog grew, and they said backlog is weighted toward the larger 320x320 systems, with use cases expanding beyond the classic spots in the network. So I find $COHR extremely attractive at these levels. I think they are going to do >$7B in rev for Fy26 and they are valued at ~29B at the time of this writing. I think the market is getting it wrong tbh. Because the stock is being treated like good quarter, messy cash flow, not LITE. While the fundamentals are increasingly multi-year visibility + capacity flywheel + margin expansion. Could I be wrong? Sure. Should you follow me blindly? Absolutely not. Again, remember my cost basis is low, I have a long term time frame, and I believe in the thesis. This allows me to have confidence on any (highly likely) dips that are coming. Especially in this tape. Who knows how low this will go. I will personally be buying at the 200ma and $170 levels again NFA of course. Please do you own DD! If you found this insightful, please do engage/ask questions and share!
10
17
1
130
102,752
Matheus Lonning retweeted
We have consistently cautioned against underestimating Chinese memory players. If you are still pigeonholing CXMT as 'just DRAM/HBM' or YMTC as 'just NAND,' you are missing the forest for the trees. "If you're still simplifying CXMT as "DRAM only" and YMTC as "NAND only," you're missing the entire picture (you're not getting it). You cannot apply standard Western business norms to Chinese state-backed tech. My contacts told me that both companies are actively developing both DRAM and NAND simultaneously. They are also developing a complete memory portfolio that can compete with Western rivals."
China memory chip maker YMTC is sampling LPDDR5 low-power DRAM chips and is developing HBM memory, media report, citing unnamed supply chain sources. YMTC’s Wuhan P3 plant expansion will begin DRAM production in the 2nd half 2026. YMTC is developing hybrid bonding techniques for HBM memory, and LPDDR5 is part of efforts to build DRAM production expertise. In its mainstay NAND memory business, Beijing has tasked YMTC with ensuring stable supplies to consumer electronics and automotive firms. $MU #SKhynix #Samsung $000660 $005930 digitimes.com.tw/tech/dt/n/s…
14
13
5
101
24,721
Matheus Lonning retweeted
If you want to listen to a mature biotech CC from today, here is one of interest from $REGN. Continues to be the Lenny and George show, and many could take several lessons here. Utmost is start off with 2 tremendous clinical assets, Eylea for wAMD et al, and Dupixent for AtDerm et al. 2 Major takehome points, 1) they continue to reformulate Eylea/extend lifespan, but seem to be in a somewhat de-emphasis mode. 2) Lenny sets forth a path to grow yearly sales of Dupixent to $17B (!!) per year. Still holding some $REGN, but also some $OCUL for their wAMD trt, and some $CRVS for the 'promise' of an oral entrant to the AtDerm market. Due diligence on all 3 required for all interested. Here is a link to the Regeneron CC, slides, and more... investor.regeneron.com/event…
5
2
17
3,596
Matheus Lonning retweeted
As many of you know, $TMDX had another very strong earnings report yesterday afternoon. Revenues up 10% QoQ and 38% YoY however it was the earnings that really crushed it... with EPS up 31% QoQ and 163% YoY. Two best things about the Q2 earnings report was net income margins coming in 22% vs 10% a year ago and the fact they raised full year guidance from 30% to 35%. July flight data was soft (just like last year) but I fully expect August and September to be better followed by a very strong Q4 (just like last year). The fact that $TMDX raised guidance means they also expect the last 5 months of the year to be strong and knowing how Waleed thinks, they will probably raise again with Q3 earnings and then beat that number by 3-5% so I fully expect $TMDX will do $630M+ for the full year which is 43% YoY. $TMDX has already started getting approvals on OCS 2.0 trials which could start in Q4 however $TMDX management said none of those revenues were included in the new guidance. Through the first half of the year $TMDX has net income margins of 20.1%, coming into the year analysts were looking for around 12% so it's been a huge upside surprise. if $TMDX can maintain 20% NIMs through the back half of the year, then they could do $3.70 in eps for the full year. Coming into Q2 earnings the analysts were looking for $1.70 for the full year so $TMDX might beat that number by more than 100%, just like they beat Q2 eps estimates by 114% This means, even with $TMDX up 11.4% today, the stock might only be trading at 32x 2025 eps with eps going 266% YoY (they did $1.01 eps last year) Looking forward, with several important tailwinds, I think $TMDX could do another 30% revenues next year depending on size of trials and revenues from European expansion (Europe is 45% of global organ transplant market) and I think net income margins could expand another 150 bps to 21.5% (assuming they finish this year around 20%) which would put non-GAAP eps in 2026 at approx $5.15 per share which means $TMDX might only be trading at 23x 2026 eps Very possible my numbers are too conservative because $TMDX continues to surprise me over and over again with their execution and efficiency. $TMDX is still my largest position and I added to it yesterday before the close at $106 and then AH at $114 and again today on the morning dip. My conviction has never been stronger and I firmly believe $TMDX will be a $250 stock in the next 12-18 months as they continue to execute at a high level. Also worth nothing $TMDX still has a 24% short interest so it's possible the shorts will need to start covering their 8M shares (8 days to cover)
29
61
4
598
287,712